Unknown

Dataset Information

Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.


ABSTRACT:

Background

Endothelin (ET-1) is one of the most potent vasoconstrictors and plays a seminal role in the pathogenesis of atherosclerosis. The present study was designed to test the hypothesis that long-term treatment with an endothelin-A (ET(A)) receptor antagonist improves coronary endothelial function in patients with early coronary atherosclerosis.

Methods and results

Forty-seven patients with multiple cardiovascular risk factors, nonobstructive coronary artery disease, and coronary endothelial dysfunction were randomized in a double-blind manner to either the ET(A) receptor antagonist atrasentan (10 mg) or placebo for 6 months. Coronary endothelium-dependent vasodilation was examined by infusing acetylcholine (10(-6) to 10(-4) mol/L) in the left anterior descending corona

SUBMITTER: Reriani M 

PROVIDER: S-EPMC2946239 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature